KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?

Future financings to progress patented hyperthermic technology aimed at improving chemotherapy therapeutic efficacy, tolerability and treatment outcomes for advanced bladder and peritoneal cancers The ...

To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...

Dr. Matthew Galsky spoke with CURE about the KEYNOTE-B15 trial results and their potential impact on muscle-invasive bladder cancer care. At the 2026 ASCO Genitourinary Cancers Symposium, the ...

The company said that these interim results support advancement into the Phase 3 RESCUE registrational trial program to evaluate NDV-01. ・Relmada also announced that it has entered into a securities ...

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

The MarketWatch News Department was not involved in the creation of this content. -- Investment led by T&J Meyer Family Foundation, joined by Varia Ventures, NW Angel Fund and other non-institutional ...